Sign in

Private company

NGM Biopharmaceuticals (United States)

Logo: ngmbio.com4

In its 2024 annual report the company says: “We are a biopharmaceutical company focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways.”7 It was founded in 2007.1 It is headquartered in South San Francisco.1

Last updated Oct 21, 2026.

Overview

Jan 1, 2007Founded1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSouth San Francisco1
  • Websitewww.ngmbio.com
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business address333 Oyster Point Boulevard, South San Francisco, Ca 940805
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • LEI5493008V5DSDZIGQOP173
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O COGENCY GLOBAL INC., 19904 Dover, United States3
  • Registered withDivision of Corporations, Department of State, 44685023

See how the biggest companies compare on our leaderboards

We are a biopharmaceutical company focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways. Our mission is to translate complex, powerful biology with rigor and urgency into life-changing medicines. Our strategy is built on a straightforward central premise: create an environment that both allows drug discovery research to thrive by focusing on powerful human biology unconstrained by therapeutic area or technology approach and remain grounded in the singular motivation of delivering impactful medicines to address critical unmet or underserved needs of patients suffering from grievous diseases. As explorers on the frontier of life-changing science, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in our pipeline…7 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-3429.1%Operating margin8
-3223.3%Net margin8
-92.0%Revenue growth, 20238
-95.8%Return on equity8

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢$118.0M

Out of $4.4M in revenue.8 The company lost money this year.

Financial statements

Revenue91011128$4.4M in 2023−94% since 2017
0$50.0M$100.0M$150.0M2017: $77.1M$77.1M20172018: $108.7M$108.7M2018+41%2019: $103.5M$103.5M2019−5%2020: $87.4M$87.4M2020−16%2021: $77.9M$77.9M2021−11%2022: $55.3M$55.3M2022−29%2023: $4.4M$4.4M2023−92%
Operating income91011128-$151.5M in 2023+769% since 2017
-$200.0M-$150.0M-$100.0M-$50.0M02017: -$17.4M-$17.4M20172018: -$4.3M-$4.3M2018−75%2019: -$49.3M-$49.3M2019+1044%2020: -$103.8M-$103.8M2020+110%2021: -$120.7M-$120.7M2021+16%2022: -$166.2M-$166.2M2022+38%2023: -$151.5M-$151.5M2023−9%
Net income91011128-$142.4M in 2023+906% since 2017
-$200.0M-$150.0M-$100.0M-$50.0M02017: -$14.2M-$14.2M20172018: -$493.0K-$493.0K2018−97%2019: -$42.8M-$42.8M2019+8581%2020: -$102.5M-$102.5M2020+139%2021: -$120.3M-$120.3M2021+17%2022: -$162.7M-$162.7M2022+35%2023: -$142.4M-$142.4M2023−12%
Fiscal year2017201820192020202120222023
Revenue$77.1M9$108.7M10$103.5M11$87.4M12$77.9M8$55.3M8$4.4M8
Research and development$79.7M9$95.7M10$129.3M11$164.0M12$161.7M8$181.1M8$118.0M8
Operating expenses$198.6M8$221.6M8$155.9M8
Operating income-$17.4M9-$4.3M10-$49.3M11-$103.8M12-$120.7M8-$166.2M8-$151.5M8
Income before tax-$120.3M8-$162.7M8-$142.4M8
Income tax-$1.1M9$09$09
Net income-$14.2M9-$493.0K10-$42.8M11-$102.5M12-$120.3M8-$162.7M8-$142.4M8
Earnings per share-$0.8511-$1.5012-$1.568-$2.038-$1.738
Earnings per share (diluted)-$0.8511-$1.5012-$1.568-$2.038-$1.738
Shares (weighted, basic)77.1M shares880.0M shares882.5M shares8
Shares (weighted, diluted)77.1M shares880.0M shares882.5M shares8

Compare NGM Biopharmaceuticals (United States) with another company

Corporate structure

NGM Biopharmaceuticals (United States) sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of NGM Biopharmaceuticals (United States)

  • COLUMN GROUP L P Filed SC 13D/A on NGM Biopharmaceuticals (United States), latest Apr 5, 2024 (5 filings since Feb 3, 2022)
  • EcoR1 Capital, LLC Filed SC 13G/A on NGM Biopharmaceuticals (United States), latest Feb 14, 2024 (2 filings since Oct 28, 2022)
  • VANGUARD GROUP INC Filed SC 13G/A on NGM Biopharmaceuticals (United States), latest Feb 13, 2024 (2 filings since Feb 9, 2023)
  • BlackRock Filed SC 13G/A on NGM Biopharmaceuticals (United States), latest Oct 6, 2023 (2 filings since Feb 3, 2023)
  • Rho Ventures V, L.P. Filed SC 13G/A on NGM Biopharmaceuticals (United States), latest Feb 13, 2023
  • NGM Biopharmaceuticals (United States) South San Francisco, California, United States
    • NGM Biopharmaceuticals Australia Pty Ltd. Subsidiary · Australia

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What NGM Biopharmaceuticals (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$51.9M8 Dec 31, 2023$51.4M8 Dec 31, 2022+0.9%
Accumulated depreciation$44.8M8 Dec 31, 2023$42.9M8 Dec 31, 2022+4.5%
Property and equipment, net$7.0M8 Dec 31, 2023$8.5M8 Dec 31, 2022−17.2%
Operating-lease assets (leased space)$08 Dec 31, 2023$2.1M8 Dec 31, 2022−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$55.8M8 Dec 31, 2023$73.5M8 Dec 31, 2022−24.0%
Marketable securities, current$88.4M8 Dec 31, 2023$198.0M8 Dec 31, 2022−55.4%
Debt securities available for sale$137.7M8 Dec 31, 2023$260.9M8 Dec 31, 2022−47.2%

Leadership

Who has led NGM Biopharmaceuticals (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David J. Woodhouse2019–2024

Chair

  1. William Jl Rieflin2019–2022

President

  1. Aetna Wun Trombley2019–2020
  2. Mangini Siobhan Nolan2022–2023

Chief financial officer

  1. David J. Woodhouse2019–2020
  2. Mangini Siobhan Nolan2020–2023
  3. Jean-Frederic Viret2023–2024

Chief operating officer

  1. Aetna Wun Trombley2019–2020
2010201520202025
Board members and other officers (15)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • NGM Biopharmaceuticals Australia Pty Ltd. Australia6

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Apr 5, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer34
  2. Mar 11, 20248-K Results of operations35
  3. Feb 26, 20248-K Entered a material agreement; Regulation FD disclosure36
  4. Jan 22, 20248-K Other events37
  5. Jan 2, 20248-K Other events38
  6. Dec 4, 20238-K Listing notice or transfer39
  7. Nov 2, 20238-K Results of operations40
  8. Oct 17, 20238-K Executive or director change41
  9. Sep 11, 20238-K Executive or director change42
  10. Aug 11, 20238-K Executive or director change43
  11. Aug 3, 20238-K Results of operations44
  12. Jun 8, 20238-K Other events45
  13. Apr 3, 2019New chief executive David J. Woodhouse becomes CEO15
  14. Jan 1, 2007Founded Founded1

Calendar

When it reported results

  1. Mar 11, 2024Reported quarterly or annual results35
  2. Nov 2, 2023Reported quarterly or annual results40
  3. Aug 3, 2023Reported quarterly or annual results44
  4. May 4, 2023Reported quarterly or annual results46
  5. Feb 28, 2023Reported quarterly or annual results47
  6. Nov 3, 2022Reported quarterly or annual results48
  7. Oct 17, 2022Reported quarterly or annual results49
  8. Aug 4, 2022Reported quarterly or annual results50

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

223 filings to the SEC since October 2021: 7 annual reports, 9 quarterly reports, 28 major events, 134 insider forms, 12 large holders, 33 other. The latest 20:

  1. Apr 15, 202415-12G EDGAR
  2. Apr 8, 2024EFFECT EDGAR
  3. Apr 8, 20244 EDGAR
  4. Apr 8, 20244 EDGAR
  5. Apr 8, 20244 EDGAR
  6. Apr 8, 20244 EDGAR
  7. Apr 8, 20244 EDGAR
  8. Apr 8, 20244 EDGAR
  9. Apr 8, 20244 EDGAR
  10. Apr 8, 20244 EDGAR
  11. Apr 8, 20244 EDGAR
  12. Apr 8, 20244 EDGAR
  13. Apr 8, 20244 OWNERSHIP DOCUMENT EDGAR
  14. Apr 8, 20244 OWNERSHIP DOCUMENT EDGAR
  15. Apr 8, 20244 OWNERSHIP DOCUMENT EDGAR
  16. Apr 8, 20244 OWNERSHIP DOCUMENT EDGAR
  17. Apr 5, 2024S-8 POS EDGAR
  18. Apr 5, 2024S-8 POS EDGAR
  19. Apr 5, 2024S-8 POS EDGAR
  20. Apr 5, 2024S-8 POS EDGAR

The 223 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

142 open-market trades by officers, directors and large owners since October 2021: 134 buys and 8 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 16, 2023COLUMN GROUP L PDirectorBuy5,840$0.62$3.6KForm 4
Nov 16, 2023COLUMN GROUP III, LP10% ownerBuy5,840$0.62$3.6KForm 4
Nov 16, 2023Kutzkey Tim10% ownerBuy5,840$0.62$3.6KForm 4
Nov 16, 2023GOEDDEL DAVID VDirectorBuy7,300$0.62$4.5KForm 4
Nov 15, 2023COLUMN GROUP L PDirectorBuy16,791$0.71$11.9KForm 4
Nov 15, 2023COLUMN GROUP III, LP10% ownerBuy16,791$0.71$11.9KForm 4
Nov 15, 2023Kutzkey Tim10% ownerBuy16,791$0.71$11.9KForm 4
Nov 15, 2023GOEDDEL DAVID VDirectorBuy19,511$0.71$13.9KForm 4
Jan 31, 2023COLUMN GROUP GP, LP10% ownerBuy176,730$5.00$883.6KForm 4
Jan 31, 2023TCG Opportunity III GP, LLC10% ownerBuy176,730$5.00$883.6KForm 4
Jan 31, 2023Ponoi Capital II, LP10% ownerBuy176,730$5.00$883.6KForm 4
Jan 31, 2023GOEDDEL DAVID VDirectorBuy176,730$5.00$883.6KForm 4
Jan 30, 2023COLUMN GROUP GP, LP10% ownerBuy7,542$5.00$37.7KForm 4
Jan 30, 2023TCG Opportunity III GP, LLC10% ownerBuy7,542$5.00$37.7KForm 4
Jan 30, 2023Ponoi Capital II, LP10% ownerBuy7,542$5.00$37.7KForm 4
Jan 30, 2023GOEDDEL DAVID VDirectorBuy7,542$5.00$37.7KForm 4
Jan 23, 2023COLUMN GROUP L PDirectorBuy9,900$5.00$49.5KForm 4
Jan 23, 2023COLUMN GROUP III-A, LP10% ownerBuy9,900$5.00$49.5KForm 4
Jan 23, 2023Ponoi II Management, LLC10% ownerBuy9,900$5.00$49.5KForm 4
Jan 23, 2023GOEDDEL DAVID VDirectorBuy9,900$5.00$49.5KForm 4

All 142 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How NGM Biopharmaceuticals (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNGM BIOPHARMACEUTICALS INC2
  • CIK0001426332
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address333 Oyster Point Boulevard, South San Francisco, CA 940802
  • Phone650-243-55552
  • Shares outstanding83,462,408 as of Mar 5, 202456
  • Public float$147.0M as of Jun 30, 202356
  • On EDGAR sinceFeb 4, 20082
  • Filings528 in all: 4 (315), 8-K (51), 3 (22), 10-Q (15), CORRESP (9), SC 13D/A (8), UPLOAD (8), DEFA14A (7)2
    All 47 form types

    SC 13G/A (7), D/A (6), SC 13G (6), 10-K (5), S-8 (5), S-8 POS (5), 10-K/A (4), 424B5 (4), D (4), DEF 14A (4), EFFECT (4), SC 13E3/A (4), SC 14D9/A (3), 10-Q/A (2), 3/A (2), 8-K/A (2), S-1/A (2), S-3 (2), SC 13E3 (2), 15-12G (1), 25-NSE (1), 4/A (1), 424B1 (1), 8-A12B (1), ARS (1), CERT (1), CT ORDER (1), DRS (1), DRS/A (1), DRSLTR (1), POS AM (1), REGDEX (1), REGDEX/A (1), S-1 (1), S-3/A (1), SC 13D (1), SC 14D9 (1), SC TO-C (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 11, 2024
    Quarterly report (10-Q) Nov 2, 2023
    Proxy statement (DEF 14A) Mar 29, 2023
    Latest 8-K (8-K) Apr 5, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
    SEC EDGAROther events
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
    SEC EDGAROther events
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56